Rep. Raul Ruiz co-introduced the Safe Step Act in April and has helped educate members of Congress about how step therapy hurts patient outcomes and care.
ACR Volunteer Leaders Visit Capitol Hill, Lobby for 5 Issues
WASHINGTON, D.C.—Dozens of rheumatology leaders met with more than 100 politicos on Capitol Hill in mid-May as part of the ACR’s annual Advocacy Leadership Conference. Armed with research and advocacy training concerning a handful of important issues, rheumatologists, rheumatology interprofessional team members, government affairs specialists and others met with federal lawmakers, legislative aides and correspondents….
ACR’s Delegation to the AMA: How We Can Continue to Advance Rheumatology
The House of Delegates (HOD) is the policy-making body of the American Medical Association (AMA), and twice a year, representatives of all seated specialties, service societies and state medical associations review hundreds of resolutions to determine which will become AMA policies. Once those policies and priorities are determined or updated, we benefit from the AMA…
CMS Rule Reflects ACR’s Advocacy, but More Patient Protections Needed
In August 2018, the Centers for Medicare and Medicaid Services (CMS) announced it would permit Medicare Advantage plans to use step therapy for Part B drugs, with a lookback period of just 108 days.1 On May 16, 2019, however, the CMS issued a final rule that extends the lookback period for Part B therapies to 365…
ACR Introduces Prior Authorization & Step Therapy Resolutions at AMA Meeting
This year, the American Medical Association (AMA) convened its annual House of Delegates (HOD) meeting June 8–12 in Chicago to discuss emerging and public health issues. Among the many policies and practices discussed: two resolutions put forth by the ACR on behalf of ACR and ARP members, one concerning prior authorization and another concerning step…
ACR Issues Position Statements on Key Rheumatology Issues
The ACR recently issued three new position statements on key issues facing rheumatologists and patients with rheumatic diseases: step therapy, affordable prescription drug pricing and a special waived test designation for synovial fluid crystal analysis performed by rheumatologists. Here is a detailed look at each. Addressing Step Therapy Step therapy or fail first protocols require patients…
State Step Therapy Laws: Not All Are Created Equal
Step therapy reform has been a hot topic and major focus of the ACR’s advocacy activity in states this legislative session. Washington, Oregon, Wisconsin and Florida are all considering step therapy bills that stand good chance of passing this legislative year. Virginia and Georgia have already passed step therapy laws. When these two new laws…
Rheumatology Advocacy in 2019
A belated Happy New Year to my fellow advocates! Here’s your first update for 2019 on what the rheumatology community should know is going on in Washington, D.C., right now. Current Climate On Jan. 3, the 116th Congress gaveled into session with Democrats in control of the House of Representatives and Republicans still the majority in the…
Gearing Up for State Legislation in 2019: 5 Issues that Need Your Attention
With a number of new legislators and new governors sworn in this month, 2019 promises to be an exciting year for state-level rheumatology advocacy. “Now is the time to reach out and share our top issues with new legislators in your state,” suggests Joseph Cantrell, ACR senior manager of state affairs. 2019 Priorities ACR Affiliate…
ACR Leaders Discuss E/M Coding Changes, Step Therapy & More
CHICAGO—ACR leaders described a series of looming legislative and regulatory threats to rheumatologists and their patients—including the proposed collapsing of evaluation and management (E/M) coding and potential changes to step therapy rules—and urged everyone in the field to make their voices heard to quash the proposals. They also recounted recent victories in the policy realm…